Clearmind Medicine (CMND) Corporate Presentation summary

Company overview and mission

• Focuses on developing novel, patent-protected psychedelic medicines for treating addictions, obesity, and mental health disorders, with initial emphasis on alcohol use disorder and obesity.

• Holds 19 patent families with 29 granted patents in major jurisdictions, and collaborates with leading universities and key opinion leaders.

• Publicly traded on NASDAQ and FSE.

Product pipeline and clinical development

• Pipeline includes treatments for alcohol use disorder, obesity, cocaine addiction, depression, drug-assisted psychotherapy, PTSD, and other mental disorders.

• Flagship molecule MEAI (5-Methoxy-2-aminoindane) is non-hallucinogenic and targets binge behaviors and addictions.

• First-in-human clinical trials (CMND-100) for alcohol use disorder to be conducted at Yale, Johns Hopkins, and IMCA Israel, focusing on safety, PK/PD, and efficacy in reducing drinking and cravings.

Market opportunity and competitive landscape

• Alcohol use disorder is a major global health issue, contributing to 2.6 million deaths annually and significant economic costs.

• Existing FDA-approved AUD treatments are expensive, have low efficacy (<30%), and poor patient compliance.

• Obesity and metabolic syndrome markets are large and growing, with MEAI showing positive pre-clinical results for weight loss and metabolic improvements.

• Clearmind is one of few companies focused on binge behaviors and holds exclusive global rights to MEAI.